Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

Opiant Pharmaceuticals logo

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$20.03
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

Movers From Yesterday
Trump Makes Major Crypto Announcement
Pay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design.
Hikma Pharmaceuticals PLC ADR (HKMPY)
Ionis Pharmaceuticals
See More Headlines

OPNT Stock Analysis - Frequently Asked Questions

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) issued its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.41. The technology company had revenue of $16.34 million for the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
11/11/2021
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Price / Cash Flow
24.75
Book Value
$9.92 per share
Price / Book
N/A

Miscellaneous

Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:OPNT) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners